BioNxt Files EU Clinical Trial Application, Completes Cladribine Batch
BioNxt submitted a Clinical Trial Application in the EU and completed GMP manufacturing of about 1,500 sublingual cladribine films for a planned bioequivalence study versus Mavenclad, pending regulatory and quality-control approvals.